A detailed history of Royal Bank Of Canada transactions in Ardelyx, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 26,564 shares of ARDX stock, worth $136,804. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,564
Previous 23,182 14.59%
Holding current value
$136,804
Previous $171,000 7.02%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.28 - $7.57 $17,856 - $25,601
3,382 Added 14.59%
26,564 $183,000
Q2 2024

Aug 14, 2024

BUY
$5.89 - $9.31 $53,121 - $83,966
9,019 Added 63.68%
23,182 $171,000
Q1 2024

Nov 05, 2024

SELL
$6.05 - $9.74 $54,564 - $87,845
-9,019 Reduced 38.91%
14,163 $103,000
Q1 2024

May 15, 2024

SELL
$6.05 - $9.74 $379,994 - $611,759
-62,809 Reduced 81.6%
14,163 $103,000
Q4 2023

Feb 14, 2024

BUY
$3.29 - $6.64 $146,951 - $296,582
44,666 Added 138.26%
76,972 $477,000
Q3 2023

Nov 14, 2023

BUY
$3.3 - $4.83 $26,871 - $39,330
8,143 Added 33.7%
32,306 $131,000
Q2 2023

Aug 14, 2023

BUY
$3.23 - $4.95 $68,356 - $104,756
21,163 Added 705.43%
24,163 $81,000
Q1 2023

May 15, 2023

SELL
$2.68 - $4.79 $6,700 - $11,975
-2,500 Reduced 45.45%
3,000 $14,000
Q4 2022

Feb 14, 2023

BUY
$1.22 - $2.85 $6,642 - $15,518
5,445 Added 9900.0%
5,500 $15,000
Q3 2022

Nov 14, 2022

BUY
$0.59 - $1.44 $32 - $79
55 New
55 $0
Q2 2022

Aug 15, 2022

SELL
$0.51 - $1.17 $3,027 - $6,946
-5,937 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$0.65 - $1.18 $11,223 - $20,375
-17,267 Reduced 74.41%
5,937 $6,000
Q4 2021

Feb 14, 2022

BUY
$0.86 - $1.7 $10,610 - $20,974
12,338 Added 113.55%
23,204 $26,000
Q3 2021

Nov 15, 2021

BUY
$1.27 - $8.17 $6,240 - $40,147
4,914 Added 82.56%
10,866 $15,000
Q2 2021

Aug 16, 2021

BUY
$6.55 - $8.98 $38,985 - $53,448
5,952 New
5,952 $45,000

Others Institutions Holding ARDX

About ARDELYX, INC.


  • Ticker ARDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 154,636,000
  • Market Cap $796M
  • Description
  • Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...
More about ARDX
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.